secwatch.observer — SEC 8-K summary
======================================

Issuer:     EAGLE PHARMACEUTICALS, INC. (—)
CIK:        0000827871
Form:       8-K
Filed at:   2024-03-08T23:59:59+00:00
Accession:  0001104659-24-032458
Event type: leadership
Sentiment:  negative
Materiality: 0.75
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eagle Pharma CFO Brian Cahill resigns effective immediately; Steven Ratoff named Interim CFO
--------------------------------------------------------------------------------

- CFO Brian Cahill resigned March 8, 2024; separation includes cash severance of $423,340 base plus $254,004 target bonus paid over 12 months.
- Director Steven Ratoff appointed Interim CFO; to receive $154,000/month for first 3 months, $77,000/month thereafter, term <12 months.
- Cahill’s time-based equity awards continue outstanding for 12 months, then vest for those scheduled during that period; performance awards forfeited.
- Consulting services of former CEO Scott Tarriff terminated effective Feb 29, 2024.
- Board committee changes: Ratoff steps down from Audit and Compensation; Jennifer Simpson named Lead Independent Director.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/827871/000110465924032458/0001104659-24-032458-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/827871/000110465924032458/tm248308d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-032458

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer